quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:08:13·106d
PRRelease
Celcuity Inc. logo
Oncolytics Biotech Inc. logo
RenovoRx Inc. logo
+1

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

CELC· Celcuity Inc.ONCY· Oncolytics Biotech Inc.RNXT· RenovoRx Inc.SLS· SELLAS Life Sciences Group Inc.
Health Care
Original source

Companies

  • CELC
    Celcuity Inc.
    Health Care
  • ONCY
    Oncolytics Biotech Inc.
    Health Care
  • RNXT
    RenovoRx Inc.
    Health Care
  • SLS
    SELLAS Life Sciences Group Inc.
    Health Care

Recent analyst ratings

  • Dec 12CELCUpdateWells Fargo$126.00
  • Nov 18CELCUpdateWolfe Research$110.00
  • Nov 17CELCUpdateH.C. Wainwright-
  • Sep 22CELCUpdateGuggenheim$110.00
  • Aug 13ONCYUpdateLake Street$7.00
  • Jul 1CELCUpdateStifel$30.00

Related

  • SEC21h
    SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.
  • SEC21h
    SEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.
  • PR1d
    RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
  • SEC7d
    SEC Form S-3 filed by RenovoRx Inc.
  • PR10d
    Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
  • INSIDER10d
    SEC Form 4 filed by Nigon Richard
  • SEC15d
    SEC Form D filed by RenovoRx Inc.
  • SEC15d
    SEC Form F-10POS filed by Oncolytics Biotech Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022